





1. TISSUE BIOPSY

- 1.1 OncoProfile Advanced 500+
- 1.2 OncoProfile Advanced 500+46
- 1.3 OncoProfile 161
- 1.4 OncoProfile 52
- 1.5 OncoProfile OVARY 46
- 1.6 OncoProfile COLORRECTAL 19
- 1.7 OncoProfile LUNG 12
- 1.8 Test BRCA Extended
- 1.9 Test BRCA






1.1 OncoProfile Advanced 500+

From a single sample, in a single test, we can offer a truly comprehensive genomic profile based on **DNA and RNA analysis of >500 genes, using next-generation sequencing (NGS).**

This panel detects:



TMB: tumor mutational burden

MSI: microsatellite instability

HRR: homologous recombination repair


LOH: genomic instability with loss of heterozygosity

+ 500
GENES

1.1 OncoProfile Advanced 500+

Hotspot Genes (n=57)			CNV Gain Genes (n=19)	Copy Number Variation and Hotspot Genes (n=107)				Gene Fusions (n=51) (Inter- and Intra-genic)	
ACVR1	IRF4	TRRAP	ABCB1	ABL1	ERBB2	MAX	PTPN11	AKT2	NF1
ATP1A1	IRS4	TSHR	CTNND2	ABL2	ERBB3	MDM4	PXDNL	ALK	NOTCH1
BCR	KLF4	WAS	DDR1	AKT1	ERBB4	MECOM	RAC1	AR	NOTCH4
BMP5	KNSTRN		EMSY	AKT2	ESR1	MEF2B	RAF1	AXL	NRG1
BTK	MAP2K2		FGF19	AKT3	EZH2	METARAR	RET	BRAF	NTRK1
CACNA1D	MED12		FGF23	ALK	FAM135B	MITF	RHEB	BRCA1	NTRK2
CD79B	MYOD1		FGF3	AR	FGFR1	MPL	RICTOR	BRCA2	NTRK3
CSF1R	NSD2		FGF4	ARAF	FGFR2	MTOR	RIT1	CDKN2A	NUTM1
CTNBN1	NT5C2		FGF9	AURKA	FGFR3	MYC	ROS1	EGFR	PDGFRA
CUL1	NTRK2		FYN	AURKC	FGFR4	MYCN	SETBP1	ERBB2	PDGFRB
CYSLTR2	NUP93		GLI3	AXL	FLT3	MYD88	SF3B1	ERBB4	PIK3CA
DGCR8	PAX5		IGF1R	BCL2	FLT4	NFE2L2	SLCO1B3	ERG	PPARG
DROSHA	PIK3CD		MCL1	BCL2L12	FOXA1	NRAS	SMC1A	ESR1	PRKACA
E2F1	PIK3CG		MDM2	BCL6	GATA2	NTRK1	SMO	ETV1	PRKACB
EPAS1	PTPRD		MYCL	BRAF	GNAS	NTRK3	SPOP	ETV4	PTEN
FGF7	RG57		RPS6KB1	CARD11	H3F3A	PCBP1	SRC	ETV5	RAD51B
FOXO2	RHOA		RPTOR	CBL	H3F3B	PDGFRA	STAT3	FGFR1	RAF1
FOXO1	RPL10		YAP1	CCND1	IDH2	PDGFRB	STAT6	FGFR2	RB1
GLI1	SIX1		YES1	CCND2	IKBKB	PIK3C2B	TERT	FGFR3	RELA
GNA11	SIX2			CCND3	IL7R	PIK3CA	TOP1	FGR	RET
GNAQ	SNCAIP			CCNE1	KDR	PIK3CB	TPMT	FLT3	ROS1
HIF1A	SQS1			CDK4	KIT	PIK3R2	U2AF1	JAK2	RSPO2
HIST1H2BD	SOX2			CDK6	KLF5	PIM1	USP8	KRAS	RSPO3
HIST1H3B	SRSF2			CHD4	KRAS	PLCG1	XPO1	MDM4	TERT
HRAS	STAT5B			DDR2	MAGOH	PPP2R1A	ZNF217	MET	
IDH1	TAF1			EGFR	MAP2K1	PPP6C	ZNF429	MYB	
IL6ST	TGFBRI			EIF1AX	MAPK1	PRKACA		MYBL1	

CNV Loss and CDS (n=206)						CDS Only Genes (n=21)	TMB only genes (n=86)			
ABRAXAS1	CD274	DSC3	HLA-A	MTAP	PRDM1	SMAD4	CALR	A1CF	LRRC7	ORC4
ACVR1B	CD276	ELF3	HLA-B	MUTYH	PRDM9	SMARCA4	CIITA	ACSM2B	MARCO	PAK5
ACVR2A	CDC73	ENO1	HNF1A	NBN	PRKAR1A	SMARCB1	CYP2D6	ADAM18	NLRC5	PCDH17
ADAMTS2	CDH1	EP300	INPP4B	NCOR1	PTCH1	SOX9	ERCC5FAS	ANO4	NOL4	PDE1A
ADAMTS2	CDK10	EPCAM	JAK1	NF1	PTEN	SPEN	ID3	ARMC4	NRXN1	PDE1C
AMER1	CDK12	EPHA2	JAK2	NF2	PTPR	STAG2	KLHL13	BRINP3	NYAP2	PLXDC2
APC	CDKN1A	ERAP1	JAK3	NOTCH1	RAD50	STK11	MTUS2	C6	OR10G8	POM121L12
ARHGAP35	CDKN1B	ERAP2	KDM5C	NOTCH2	RAD51	SUFU	PSMB10	C8A	OR2G6	PPFIA2
ARID1A	CDKN2A	ERCC2	KDM6A	NOTCH3	RAD51B	TAP1	PSMB8	C8B	OR2L13	RBP3
ARID1B	CDKN2B	ERCC4	KEAP1	NOTCH4	RAD51C	TAP2	PSMB9	CANX	OR2L2	REG1A
ARID2	CDKN2C	ERRF1	KMT2A	PALB2	RAD51D	TBX3	RNASEH2C	CASR	OR2L8	REG1B
ARID5B	CHEK1	ETV6	KMT2B	PARP1	RAD52	TCF7L2	RPL22	CD163	OR2M3	REG3A
ASXL1	CHEK2	FANCA	KMT2C	PARP2	RAD54L	TET2	RPL5	CNTN6	OR2T3	REG3G
ASXL2	CIC	FANCC	KMT2D	PARP3	RASA1	TGFBFR2	RUNX1T1	CNTNAP4	OR2T33	RPTN
ATM	CREBBP	FANCD2	LARP4B	PARP4	RASA2	TNFAIP3	SDHC	CNTNAP5	OR2T4	RUND3B
ATR	CSMD3	FANCE	LATS1	PBRM1	RB1	TNFRSF14	SOC31	COL11A1	OR2W3	SH3RF2
ATRX	CTCF	FANCF	LATS2	PDCD1	RBM10	TP53	STAT1	DCAF4L2	OR4A15	SLC15A2
AXIN1	CTLA4	FANCG	MAP2K4	PDCD1LG2	RECQL4	TP63	TMEM132D	DCDC1	OR4C15	SLC8A1
AXIN2	CUL3	FANCI	MAP2K7	PDIA3	RNASEH2A	TPP2	UGT1A1	GALNT17	OR4C6	SYT10
B2M	CUL4A	FANCL	MAP3K1	PGD	RNASEH2B	TSC1	ZBTB20	GPR158	OR4M1	SYT16
BAP1	CUL4B	FANCM	MAP3K4	PHF6	RNF43	TSC2		GRID2	OR4M2	TAPBP
BARD1	CYLD	FAT1	MAPK8	PIK3R1	RPA1	USP9X		HCN1	OR5D18	TPTE
BCOR	CYP2C9	FBXW7	MEN1	PMS1	RUNX1	VHL		HLA-C	OR5F1	TRHDE
BLM	DAXX	FUBP1	MGA	PMS2	SDHA	WT1		KCND2	OR5L1	TRIM48
BMPR2	DDX3X	GATA3	MLH1	POLD1	SDHB	XRCC2		KCNH7	OR5L2	TRIM51
BRCA1	DICER1	GNA13	MLH3	POLE	SDHD	XRCC3		KEL	OR6F1	ZIM3
BRCA2	DNMT3A	GPS2	MRE11	POT1	SETD2	ZFXH3		KIR3DL1	OR8H2	ZNF479
BRIP1	DOCK3	HDAC2	MSH2	PPM1D	SLX4	ZMYM3		KRTAP2-1	OR8I2	ZNF536
CASP8	DPYD	HDAC9	MSH3	PPP2R2A	SMAD2	ZRSR2		KRTAP6-2	OR8U1	
CBFB	DSC1		MSH6							




+



1.2 OncoProfile Advanced 500+46

OncoProfile Advanced 500+46 has the same basis as OncoProfile Advanced 500+ with the addition of 46 genes involved in the HRR pathway, useful for assessing HRD and selecting patients who are candidates for **PARP** inhibitors.

This panel detects:



TMB: tumor mutational burden

MSI: microsatellite instability

HRR: homologous recombination repair

LOH: genomic instability with loss of heterozygosity

GIM: Genomic Instability Metric

HRD: Homologous Recombination

1.2 OncoProfile Advanced 500+ 46

CDS Genes (n=46)

<i>ABRAXAS1</i>	<i>POLD1</i>
<i>ATM</i>	<i>POLE</i>
<i>ATR</i>	<i>PPP2R2A</i>
<i>BAP1</i>	<i>PTEN</i>
<i>BARD1</i>	<i>RAD50</i>
<i>BLM</i>	<i>RAD51</i>
<i>BRCA1</i>	<i>RAD51B</i>
<i>BRCA2</i>	<i>RAD51C</i>
<i>BRIP1</i>	<i>RAD51D</i>
<i>CDK12</i>	<i>RAD54L</i>
<i>CHEK1</i>	<i>RNASEH2A</i>
<i>CHEK2</i>	<i>RNASEH2B</i>
<i>FANCA</i>	<i>RNASEH2C</i>
<i>FANCC</i>	<i>RPA1</i>
<i>FANCD2</i>	<i>SLX4</i>
<i>FANCE</i>	<i>TP53</i>
<i>FANCF</i>	<i>XRCC2</i>
<i>FANCG</i>	<i>XRCC3</i>
<i>FANCI</i>	
<i>FANCL</i>	
<i>FANCM</i>	
<i>MRE11</i>	
<i>NBN</i>	
<i>PALB2</i>	
<i>PARP1</i>	
<i>PARP2</i>	
<i>PARP3</i>	

CNV genes (n=45)

<i>ABRAXAS1</i>	<i>POLD1</i>
<i>ATM</i>	<i>POLE</i>
<i>ATR</i>	<i>PPP2R2A</i>
<i>BAP1</i>	<i>PTEN</i>
<i>BARD1</i>	<i>RAD50</i>
<i>BLM</i>	<i>RAD51</i>
<i>BRCA1</i>	<i>RAD51B</i>
<i>BRCA2</i>	<i>RAD51C</i>
<i>BRIP1</i>	<i>RAD51D</i>
<i>CDK12</i>	<i>RAD54L</i>
<i>CHEK1</i>	<i>RNASEH2A</i>
<i>CHEK2</i>	<i>RNASEH2B</i>
<i>FANCA</i>	<i>RPA1</i>
<i>FANCC</i>	<i>SLX4</i>
<i>FANCD2</i>	<i>TP53</i>
<i>FANCE</i>	<i>XRCC2</i>
<i>FANCF</i>	<i>XRCC3</i>
<i>FANCG</i>	
<i>FANCI</i>	
<i>FANCL</i>	
<i>FANCM</i>	
<i>MRE11</i>	
<i>NBN</i>	
<i>PALB2</i>	
<i>PARP1</i>	
<i>PARP2</i>	
<i>PARP3</i>	

1.2 OncoProfile Advanced 500+46

Hotspot Genes (n=57)			CNV Gain Genes (n=19)	Copy Number Variation and Hotspot Genes (n=107)				Gene Fusions (n=51) (Inter- and Intra-genic)	
ACVR1	IRF4	TRRAP	ABCB1	ABL1	ERBB2	MAX	PTPN11	AKT2	NF1
ATP1A1	IRS4	TSHR	CTNND2	ABL2	ERBB3	MDM4	PXDNL	ALK	NOTCH1
BCR	KLF4	WAS	DDR1	AKT1	ERBB4	MECOM	RAC1	AR	NOTCH4
BMP5	KNSTRN		EMSY	AKT2	ESR1	MEF2B	RAF1	AXL	NRG1
BTK	MAP2K2		FGF19	AKT3	EZH2	METARAR	RET	BRAF	NTRK1
CACNA1D	MED12		FGF23	ALK	FAM135B	MITF	RHEB	BRCA1	NTRK2
CD79B	MYOD1		FGF3	AR	FGFR1	MPL	RICTOR	BRCA2	NTRK3
CSF1R	NSD2		FGF4	ARAF	FGFR2	MTOR	RIT1	CDKN2A	NUTM1
CTNNB1	NT5C2		FGF9	AURKA	FGFR3	MYC	ROS1	EGFR	PDGFRA
CUL1	NTRK2		FYN	AURKC	FGFR4	MYCN	SETBP1	ERBB2	PDGFRB
CYSLTR2	NUP93		GLI3	AXL	FLT3	MYD88	SF3B1	ERBB4	PIK3CA
DGCR8	PAX5		IGF1R	BCL2	FLT4	NFE2L2	SLCO1B3	ERG	PPARG
DROSHA	PIK3CD		MCL1	BCL2L12	FOXA1	NRAS	SMC1A	ESR1	PRKACA
E2F1	PIK3CG		MDM2	BCL6	GATA2	NTRK1	SMO	ETV1	PRKACB
EPAS1	PTPRD		MYCL	BRAF	GNAS	NTRK3	SPOP	ETV4	PTEN
FGF7	RG57		RPS6KB1	CARD11	H3F3A	PCBP1	SRC	ETV5	RAD51B
FOXJ2	RHOA		RPTOR	CBL	H3F3B	PDGFRA	STAT3	FGFR1	RAF1
FOXO1	RPL10		YAP1	CCND1	IDH2	PDGFRB	STAT6	FGFR2	RB1
GLI1	SIX1		YES1	CCND2	IKBKB	PIK3C2B	TERT	FGFR3	RELA
GNA11	SIX2			CCND3	IL7R	PIK3CA	TOP1	FGR	RET
GNAQ	SNCAIP			CCNE1	KDR	PIK3CB	TPMT	FLT3	ROS1
HIF1A	SQS1			CDK4	KIT	PIK3R2	U2AF1	JAK2	RSPO2
HIST1H2BD	SOX2			CDK6	KLF5	PIM1	USP8	KRAS	RSPO3
HIST1H3B	SRSF2			CHD4	KRAS	PLCG1	XPO1	MDM4	TERT
HRAS	STAT5B			DDR2	MAGOH	PPP2R1A	ZNF217	MET	
IDH1	TAF1			EGFR	MAP2K1	PPP6C	ZNF429	MYB	
IL6ST	TGFBRI			EIF1AX	MAPK1	PRKACA		MYBL1	

CNV Loss and CDS (n=206)						CDS Only Genes (n=21)	TMB only genes (n=86)			
ABRAXAS1	CD274	DSC3	HLA-A	MTAP	PRDM1	SMAD4	CALR	A1CF	LRRC7	ORC4
ACVR1B	CD276	ELF3	HLA-B	MUTYH	PRDM9	SMARCA4	CIITA	ACSM2B	MARCO	PAK5
ACVR2A	CDC73	ENO1	HNF1A	NBN	PRKAR1A	SMARCB1	CYP2D6	ADAM18	NLRC5	PCDH17
ADAMTS12	CDH1	EP300	INPP4B	NCOR1	PTCH1	SOX9	ERCC5FAS	ANO4	NOL4	PDE1A
ADAMTS2	CDK10	EPCAM	JAK1	NF1	PTEN	SPEN	ID3	ARMC4	NRXN1	PDE1C
AMER1	CDK12	EPHA2	JAK2	NF2	PTPR	STAG2	KLHL13	BRINP3	NYAP2	PLXDC2
APC	CDKN1A	ERAP1	JAK3	NOTCH1	RAD50	STK11	MTUS2	C6	OR10G8	POM121L12
ARHGAP35	CDKN1B	ERAP2	KDM5C	NOTCH2	RAD51	SUFU	PSMB10	C8A	OR2G6	PPFIA2
ARID1A	CDKN2A	ERCC2	KDM6A	NOTCH3	RAD51B	TAP1	PSMB8	C8B	OR2L13	RBP3
ARID1B	CDKN2B	ERCC4	KEAP1	NOTCH4	RAD51C	TAP2	PSMB9	CANX	OR2L2	REG1A
ARID2	CDKN2C	ERRF1	KMT2A	PALB2	RAD51D	TBX3	RNASEH2C	CASR	OR2L8	REG1B
ARID5B	CHEK1	ETV6	KMT2B	PARP1	RAD52	TCF7L2	RPL22	CD163	OR2M3	REG3A
ASXL1	CHEK2	FANCA	KMT2C	PARP2	RAD54L	TET2	RPL5	CNTN6	OR2T3	REG3G
ASXL2	CIC	FANCC	KMT2D	PARP3	RASA1	TGFBP2	RUNX1T1	CNTNAP4	OR2T33	RPTN
ATM	CREBBP	FANCD2	LARP4B	PARP4	RASA2	TNFAIP3	SDHC	CNTNAP5	OR2T4	RUND3B
ATR	CSMD3	FANCE	LATS1	PBRM1	RB1	TNFRSF14	SOC3	COL11A1	OR2W3	SH3RF2
ATRX	CTCF	FANCF	LATS2	PDCD1	RBM10	TP53	STAT1	DCAF4L2	OR4A15	SLC15A2
AXIN1	CTLA4	FANCG	MAP2K4	PDCD1LG2	RECQL4	TP63	TMEM132D	DCDC1	OR4C15	SLC8A1
AXIN2	CUL3	FANCI	MAP2K7	PDIA3	RNASEH2A	TPP2	UGT1A1	GALNT17	OR4C6	SYT10
B2M	CUL4A	FANCL	MAP3K1	PGD	RNASEH2B	TSC1	ZBTB20	GPR158	OR4M1	SYT16
BAP1	CUL4B	FANCM	MAP3K4	PHF6	RNF43	TSC2		GRID2	OR4M2	TAPBP
BARD1	CYLD	FAT1	MAPK8	PIK3R1	RPA1	USP9X		HCN1	OR5D18	TPTE
BCOR	CYP2C9	FBXW7	MEN1	PMS1	RUNX1	VHL		HLA-C	OR5F1	TRHDE
BLM	DAXX	FUBP1	MGA	PMS2	SDHA	WT1		KCND2	OR5L1	TRIM48
BMPR2	DDX3X	GATA3	MLH1	POLD1	SDHB	XRCC2		KCNH7	OR5L2	TRIM51
BRCA1	DICER1	GNA13	MLH3	POLE	SDHD	XRCC3		KEL	OR6F1	ZIM3
BRCA2	DNMT3A	GPS2	MRE11	POT1	SETD2	ZFXH3		KIR3DL1	OR8H2	ZNF479
BRIP1	DOCK3	HDAC2	MSH2	PPM1D	SLX4	ZMYM3		KRTAP2-1	OR8I2	ZNF536
CASP8	DPYD	HDAC9	MSH3	PPP2R2A	SMAD2	ZRSR2		KRTAP6-2	OR8U1	
CBFB	DSC1		MSH6							



1.3 OncoProfile 161

Capable of identifying pathogenic variants by evaluating 161 genes proven to be useful in cancer.

This test includes:

- Extensive coverage of kinase domains in tyrosine kinase receptors, which increases the chances of detecting relevant functional mutations in addition to prevalent pathological variants that are informative for treatment decisions (**ALK, BRAF, DDR2, EGFR, KIT, ROS1, NTKR, MET, PDGFRA, RET, ERBB2, PIK3, IDH1**).
- Broad coverage of genes related to DNA repair pathways (31 genes).
- Broad coverage of genes such as **MAPK, PIK3**, as well as genes related to the cell cycle.

This panel detects:

Hotspot
SNV e
Indels

Fusion
Genes

CNVs

1.3 OncoProfile 161

Hotspot genes				Full-length genes		
AKT1	ESR1	KIT	PDGFRB	ARID1A	FBXW7	PTEN
AKT2	EZH2	KNSTRN	PIK3CB	ATM	MLH1	RAD50
AKT3	FGFR1	KRAS	PIK3CA	ATR	MRE11	RAD51
ALK	FGFR2	MAGOH	PPP2R1A	ATRX	MSH6	RAD51B
AR	FGFR3	MAP2K1	PTPN11	BAP1	MSH2	RAD51C
ARAF	FGFR4	MAP2K2	RAC1	BRCA1	NBN	RAD51D
AXL	FLT3	MAP2K4	RAF1	BRCA2	NF1	RNF43
BRAF	FOXL2	MAPK1	RET	CDK12	NF2	RB1
BTK	GATA2	MAX	RHEB	CDKN1B	NOTCH1	SETD2
CBL	GNA11	MDM4	RHOA	CDKN2A	NOTCH2	SLX4
CCND1	GNAQ	MED12	ROS1	CDKN2B	NOTCH3	SMARCA4
CDK4	GNAS	MET	SF3B1	CHEK1	PALB2	SMARCB1
CDK6	H3F3A	MTOR	SMAD4	CREBBP	PIK3R1	STK11
CHEK2	HIST1H3B	MYC	SMO	FANCA	PMS2	TP53
CSF1R	HNF1A	MYCN	SPOP	FANCD2	POLE	TSC1
CTNNB1	HRAS	MYD88	SRC	FANCI	PTCH1	TSC2
DDR2	IDH1	NFE2L2	STAT3			
EGFR	IDH2	NRAS	TERT			
ERBB2	JAK1	NTRK1	TOP1			
ERBB3	JAK2	NTRK2	U2AF1			
ERBB4	JAK3	NTRK3	XPO1			
ERCC2	KDR	PDGFRA				

Copy number genes		Gene Fusions (n=51) (inter-and intragenic)		
AKT1	FGFR4	AKT2	FGFR2	NUTM1
AKT2	FLT3	ALK	FGFR3	PDGFRA
AKT3	IGF1R	AR	FGR	PDGFRB
ALK	KIT	AXL	FLT3	PIK3CA
AXL	KRAS	BRCA1	JAK2	PRKACA
AR	MDM2	BRCA2	KRAS	PRKACB
BRAF	MDM4	BRAF	MDM4	PTEN
CCND1	MET	CDKN2A	MET	PPARG
CCND2	MYC	EGFR	MYB	RAD51B
CCND3	MYCL	ERBB2	MYBL1	RAF1
CCNE1	MYCN	ERBB4	NF1	RB1
CDK2	NTRK1	ERG	NOTCH1	RELA
CDK4	NTRK2	ESR1	NOTCH4	RET
CDK6	NTRK3	ETV1	NRG1	ROS1
EGFR	PDGFRA	ETV4	NTRK1	RSPO2
ERBB2	PDGFRB	ETV5	NTRK2	RSPO3
ESR1	PIK3CB	FGFR1	NTRK3	TERT
FGF19	PIK3CA			
FGF3	PPARG			
FGFR1	RICTOR			
FGFR2	TERT			
FGFR3				

1.4 OncoProfile 52

- Sensitive detection of variants in 52 genes with high relevance in multiple types of cancer.
- Genes carefully selected for their usefulness in the management and treatment of oncological processes.
- Allows simultaneous DNA and RNA results to be obtained.
- Compatible with samples of as little as 10 ng of genetic material from paraffin-embedded tumor tissue.


This panel detects:

Hotspot
SNV e
Indels

Fusion
Genes


CNVs

Hotspot Genes (n=35)			Copy Number genes (n=19)		Fusion Genes (n=23)	
AKT1	HRAS	RET	ALK	MYCN	ABL1	NTRK2
ALK	IDH1	ROS1	AR	PDGFRA	AKT3	NTRK3
AR	IDH2	SMO	BRAF	PIK3CA	ALK	PDGFRA
BRAF	JAK1		CCND1		AXL	PPARG
CDK4	JAK2		CDK4		BRAF	RAF1
CTNNB1	JAK3		CDK6		EGFR	RET
DDR2	KIT		EGFR		ERBB2	ROS1
EGFR	KRAS		ERBB2		ERG	
ERBB2	MAP2K1		FGFR1		ETV1	
ERBB3	MAP2K2		FGFR2		ETV4	
ERBB4	MET		FGFR3		ETV5	
ESR1	MTOR		FGFR4		FGFR1	
FGFR2	NRAS		KIT		FGFR2	
FGFR3	PDGFRA		KRAS		FGFR3	
GNA11	PIK3CA		MET		MET	
GNAQ	RAF1		MYC		NTRK1	



1.5 OncoProfile OVARY 46

This test analyzes:



This panel covers 46 genes involved in the HRR pathway:


CDS Genes (n=46)		CNV genes (n=45)	
ABRAXAS1	POLD1	ABRAXAS1	POLD1
ATM	POLE	ATM	POLE
ATR	PPP2R2A	ATR	PPP2R2A
BAP1	PTEN	BAP1	PTEN
BARD1	RAD50	BARD1	RAD50
BLM	RAD51	BLM	RAD51
BRCA1	RAD51B	BRCA1	RAD51B
BRCA2	RAD51C	BRCA2	RAD51C
BRIP1	RAD51D	BRIP1	RAD51D
CDK12	RAD54L	CDK12	RAD54L
CHEK1	RNASEH2A	CHEK1	RNASEH2A
CHEK2	RNASEH2B	CHEK2	RNASEH2B
FANCA	RNASEH2C	FANCA	RPA1
FANCC	RPA1	FANCC	SLX4
FANCD2	SLX4	FANCD2	TP53
FANCE	TP53	FANCE	XRCC2
FANCF	XRCC2	FANCF	XRCC3
FANCG	XRCC3	FANCG	
FANCI		FANCI	
FANCL		FANCL	
FANCM		FANCM	
MRE11		MRE11	
NBN		NBN	
PALB2		PALB2	
PARP1		PARP1	
PARP2		PARP2	
PARP3		PARP3	



1.6 OncoProfile COLORRECTAL 19

It includes 19 genes, including the **MMR** (mismatch repair pathway) genes **MLH1**, **MSH2**, **MSH6**, **PMS2**, and other genes of recognized clinical utility in colorectal cancer such as **APC**, **MUTYH**, **KRAS**, and **NRAS**.

This panel detects:



Genes	MLH1, MSH2, MSH6, PMS2, APC, AXIN2, CDH1, CHEK2, EPCAM, MSH3, MUTYH, POLD1, POLE, PTEN, SMAD4, TP53, KRAS, NRAS, BRAF
Test value	Genetic testing of solid tumors. Confirmation or exclusion of Lynch syndrome. Cancer treatment management. Risk assessment for hereditary cancer syndromes associated with these genes: Lynch syndrome, familial adenomatous polyposis (FAP), and colorectal polyposis.




1.7 OncoProfile LUNG 12

AUsing paraffin-embedded tumor tissue samples (FFPE) and massive sequencing techniques, our test is capable of evaluating 12 genes with proven clinical utility in genetic material extracted from this type of sample.

This test provides results related to tumor heterogeneity and the detection of treatment-resistant clones.

This panel detects:



Genes		Fusion Genes
ALK	NRAS	ALK
BRAF	PIK3CA	ROS1
EGFR	RET	RET
ERBB2	ROS1	
KRAS	TP53	
MAP2K1		
MET		

- 12 genes
- Librería única a partir de ADN y ARN
- 58 amplicons
- >169 hotspots e Indels




1.8 Test BRCA Extended

It analyzes 21 genes that are fundamental in the genetic study of **breast, ovarian, and prostate cancer**.

It provides information on pathogenic variants in the **BRCA1 and BRCA2** genes, along with all the genes recommended by the **SEOM** (Spanish Society of Medical Oncology), and other genes related to homologous DNA recombination with described clinical utility.

This panel detects:



Genes	BRCA1, BRCA2, ATM, BARD1, BRIP1, CDH1, CDK12, CHEK2, FANCD2, MRE11, MLH1, MSH2, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, TP53, PMS2
Test Value	Cancer management (possibility of treatment with PARP inhibitors). Risk assessment for hereditary breast, ovarian, and prostate cancer. It is mainly used for the genetic study of breast and ovarian cancer, but it also has informative value in prostate cancer.



1.9 Test BRCA


The percentage of prostate cancers in which mutations in the **BRCA** genes are found reaches up to 40%.

In the general population, it is estimated that 1.3% of women will develop ovarian cancer during their lifetime. Mutations in **BRCA1 and BRCA2** are thought to cause around **15-20% of ovarian cancers in general**.

Mutations in **BRCA1 and BRCA2** are thought to cause about **16% of hereditary breast cancers**, which in turn account for between 5% and 10% of all breast cancers in women.

BRCA1 and BRCA2 are the genes most frequently involved and carry a considerable lifetime risk of breast cancer (**72% for BRCA1 and 69% for BRCA2, up to age 80**).

This panel detects:



Genes

BRCA1 y BRCA2

Test Value

It is mainly used for the genetic study of breast, ovarian, and prostate cancer, but it also provides valuable information in pancreatic cancer.

Assessment of the risk of cancer associated with mutations in the BRCA1 and BRCA2 genes.
Management of cancer treatment and decisions regarding treatment with PARP inhibitors.
